Advanced search
Publication Cover
Expert Review of Clinical Immunology Volume 13, 2017 - Issue 2
Submit an article Journal homepage
810
Views
8
CrossRef citations to date
0
Altmetric
Review

Shared target antigens on cancer cells and tissue stem cells: go or no-go for CAR T cells?

Andreas A. HombachCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany;Department I of Internal Medicine, University Hospital Cologne, Cologne, GermanyView further author information
&
Hinrich AbkenCenter for Molecular Medicine Cologne, University of Cologne, Cologne, Germany;Department I of Internal Medicine, University Hospital Cologne, Cologne, GermanyCorrespondence[email protected]
View further author information
Pages 151-155 | Received 24 May 2016, Accepted 04 Aug 2016, Published online: 22 Aug 2016

Citations (8)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Xiao Chen Ma, Xiao Lv & Ying Li. (2023) Development of CD30 CAR-T cells in refractory or relapsed Hodgkin’s lymphoma. Expert Review of Hematology 0:0, pages 1-7.
Read now
Carole Fournier, François Martin, Laurence Zitvogel, Guido Kroemer, Lorenzo Galluzzi & Lionel Apetoh. (2017) Trial Watch: Adoptively transferred cells for anticancer immunotherapy. OncoImmunology 6:11.
Read now

Articles from other publishers (6)

Vincenzo Maria Perriello, Maria Caterina Rotiroti, Ilaria Pisani, Stefania Galimberti, Gaia Alberti, Giulia Pianigiani, Valerio Ciaurro, Andrea Marra, Marcella Sabino, Valentina Tini, Giulio Spinozzi, Federica Mezzasoma, Francesco Morena, Sabata Martino, Domenico Salerno, Julian François Ashby, Brittany Wingham, Marta Serafini, Maria Paola Martelli, Brunangelo Falini, Andrea Biondi & Sarah Tettamanti. (2023) IL-3-zetakine combined with a CD33 costimulatory receptor as a dual CAR approach for safer and selective targeting of AML. Blood Advances 7:12, pages 2855-2871.
Crossref
Van To, Vera J. Evtimov, Graham Jenkin, Aleta Pupovac, Alan O. Trounson & Richard L. Boyd. (2022) CAR-T cell development for Cutaneous T cell Lymphoma: current limitations and potential treatment strategies. Frontiers in Immunology 13.
Crossref
Cristina Ferreras, Lucía Fernández, Laura Clares-Villa, Marta Ibáñez-Navarro, Carla Martín-Cortázar, Isabel Esteban-Rodríguez, Javier Saceda & Antonio Pérez-Martínez. (2021) Facing CAR T Cell Challenges on the Deadliest Paediatric Brain Tumours. Cells 10:11, pages 2940.
Crossref
Tamer Othman, Alex Herrera & Matthew Mei. (2021) Emerging Therapies in Relapsed and Refractory Hodgkin Lymphoma: What Comes Next After Brentuximab Vedotin and PD-1 Inhibition?. Current Hematologic Malignancy Reports 16:1, pages 1-7.
Crossref
Natalie S. Grover & Barbara Savoldo. (2019) Challenges of driving CD30-directed CAR-T cells to the clinic. BMC Cancer 19:1.
Crossref
Astrid Holzinger & Hinrich Abken. 2017. Immunotherapy - Myths, Reality, Ideas, Future. Immunotherapy - Myths, Reality, Ideas, Future.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.